John Strickler, MD, discusses targeting c-Met as a biomarker in gastric and gastroesophageal junction cancers.

Meredith McKean, MD, MPH, discussed findings from a longer-term follow-up study evaluating fianlimab plus cemiplimab for the ...

In an interview with Targeted Oncology, Courtney Van Houzen, PharmD, shared her experience in bringing bispecific antibody ...

John M. Burke, MD, examines how new obesity treatments, such as GLP-1 agonists, might influence future cancer rates.

Eric Cheung, DO, Targeted Oncology’s second 2024 Oncology Icon, discussed his journey in oncology, advances in treatment, and ...

Amy Selly, CNP, AOCNP, discusses how physicians can support their patients' survivorship journeys.

The approval of inavolisib is supported by findings from the phase 3 INAVO120 study evaluating the agent plus palbociclib and ...

According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...

The first patient with advanced gastric and gastroesophageal cancer has been dosed in a trial combining PT886 with ...

Samer A. Al'Hadidi, MD, MS, reviewed the benefits of cilta-cel in the subgroup analysis of CARTITUDE-4 in patients with ...

Panelists discuss how updates from the POD1UM-303/InterAACT2 trial presented at European Society for Medical Oncology Congress (ESMO) 2024 shed light on retifanlimab’s potential role in advancing ...

Yufei Liu, MD, PhD, discussed the importance of careful data interpretation to accurately assess the efficacy of new ...